Patents by Inventor Emma Elizabeth BASTON

Emma Elizabeth BASTON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HIV Specific Binding Molecules
    Publication number: 20230265191
    Abstract: Specific binding molecules, including T cell receptors (TCRs), which bind the HLA-A*02 restricted peptide SLYNTVATL (SEQ ID NO: 1) derived from the HIV Gag gene product, p17 are presented. TCRs of the present invention comprise non-natural mutations within the alpha and/or beta variable domains relative to a native TCR. The specific binding molecules of the invention have improved stability and/or yield and yet unexpectedly retain the advantageous properties of the specific binding molecules from which they are derived. Such specific binding molecules are particularly useful in the development of soluble immunotherapeutic reagents for the treatment of HIV infected individuals.
    Type: Application
    Filed: October 5, 2022
    Publication date: August 24, 2023
    Inventors: Marcin Dembek, Luis Filipe da Silva Godinho, Praveen Singh, Emma Elizabeth Baston, Andrew Creese, Thomas Minshull, Pranav Bheamadu
  • T cell receptors specific for the NY-ESO-1 tumor antigen-HLA-A*02 complex
    Patent number: 11639374
    Abstract: The present invention relates to T cell receptors (TCRs) which bind the HLA-A*02 restricted peptide SLLMWITQC derived from the cancer antigen NY-ESO-1. Said TCRs may comprise mutations within the alpha and/or beta variable domains relative to a native NY-ESO-1 TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: May 2, 2023
    Assignee: IMMUNOCORE LIMITED
    Inventors: Fiona Chester, Andrew Alexander Knox, Jonathan Patrick Lowther, Viren Vinubhai Patel, Emma Elizabeth Baston, Ruth Martinez Hague
  • T CELL RECEPTORS SPECIFIC FOR THE NY-ESO-1 TUMOR ANTIGEN-HLA-A*02 COMPLEX
    Publication number: 20190002523
    Abstract: The present invention relates to T cell receptors (TCRs) which bind the HLA-A*02 restricted peptide SLLMWITQC derived from the cancer antigen NY-ESO-1. Said TCRs may comprise mutations within the alpha and/or beta variable domains relative to a native NY-ESO-1 TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.
    Type: Application
    Filed: December 22, 2016
    Publication date: January 3, 2019
    Inventors: Fiona CHESTER, Andrew Alexander KNOX, Jonathan Patrick LOWTHER, Viren Vinubhai PATEL, Emma Elizabeth BASTON, Ruth Martinez HAGUE